Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lineage Cell Therapeutics, Inc. LCTX

Healthcare  —  Biotechnology
1.03 0.08 8.42% as of 25 Sep
Market cap
$239.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Lineage Cell Therapeutics, Inc. (LCTX) Business Profile

Updated before January 2025

Company Overview

Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapies. The company was founded in 1990 and is headquartered in Carlsbad, California, USA. Initially established as BioTime, Inc., the company rebranded to Lineage Cell Therapeutics in 2019 to better reflect its focus on regenerative medicine and cell therapy technologies.

Lineage Cell Therapeutics is led by a team of experienced executives and scientists. The company’s CEO, Brian M. Culley, has extensive experience in the biotechnology industry, particularly in advancing innovative therapies through clinical development and commercialization. Other key members of the leadership team include Dr. Gabriel Nistor, Chief Scientific Officer, and Jill Howe, Chief Financial Officer. Together, they bring a wealth of expertise in cell therapy, regenerative medicine, and corporate strategy.

Core Business Segments

Lineage Cell Therapeutics operates in the field of regenerative medicine, with a focus on developing cell-based therapies for unmet medical needs. The company’s core business segments include:

1. Ophthalmology

  • OpRegen®: A cell therapy product designed for the treatment of dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. OpRegen® uses retinal pigment epithelial (RPE) cells derived from pluripotent stem cells to replace damaged cells in the retina.

2. Neurology

  • AST-OPC1: A therapy aimed at treating spinal cord injuries. AST-OPC1 consists of oligodendrocyte progenitor cells (OPCs) that are transplanted into the injured spinal cord to promote repair and functional recovery.

3. Oncology

  • VAC2: An allogeneic cancer immunotherapy platform designed to stimulate the immune system to target and destroy cancer cells. VAC2 is currently being evaluated for its potential to treat non-small cell lung cancer (NSCLC).

4. Research and Development Services

  • Lineage also provides research and development services to other biotechnology companies and academic institutions. These services include cell line development, manufacturing, and preclinical testing.

Business Model

Lineage Cell Therapeutics operates on a business model that integrates cutting-edge science with strategic partnerships to advance its pipeline of cell therapy products. The company generates revenue through the following channels:

  1. Collaborations and Licensing Agreements: Lineage partners with pharmaceutical companies, research institutions, and government agencies to co-develop and commercialize its therapies. These partnerships often include milestone payments, royalties, and research funding.

  2. Grant Funding: The company secures non-dilutive funding from organizations such as the California Institute for Regenerative Medicine (CIRM) to support its research and development efforts.

  3. Product Development and Commercialization: As its therapies progress through clinical trials and receive regulatory approval, Lineage plans to generate revenue through product sales and licensing agreements.

  4. Contract Services: Lineage offers contract manufacturing and research services to other biotech companies, leveraging its expertise in cell therapy development.

Strategic Direction

Lineage Cell Therapeutics is focused on advancing its pipeline of cell therapy products through clinical development and regulatory approval. The company’s strategic priorities include:

  1. Expanding Clinical Trials: Lineage is actively conducting clinical trials for its lead programs, including OpRegen® for dry AMD and AST-OPC1 for spinal cord injuries. The company aims to expand these trials to include larger patient populations and additional indications.

  2. Enhancing Manufacturing Capabilities: To support the commercialization of its therapies, Lineage is investing in scalable and cost-effective manufacturing processes for cell-based products.

  3. Exploring New Indications: The company is exploring the potential of its cell therapy platforms to address additional diseases, such as Parkinson’s disease, stroke, and other neurodegenerative conditions.

  4. Sustainability Goals: Lineage is committed to sustainable practices in its operations, including reducing waste and energy consumption in its manufacturing processes.

  5. Strategic Partnerships: The company continues to seek partnerships with pharmaceutical companies and research institutions to accelerate the development and commercialization of its therapies.

Competitive Landscape

Lineage Cell Therapeutics operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  1. Astellas Pharma: A global pharmaceutical company with a focus on regenerative medicine and cell therapy.
  2. Bluebird Bio: A biotechnology company developing gene and cell therapies for severe genetic diseases and cancer.
  3. Sangamo Therapeutics: A leader in genomic medicine, developing cell and gene therapies for a range of diseases.
  4. Fate Therapeutics: A clinical-stage biopharmaceutical company focused on cellular immunotherapies for cancer and immune disorders.
  5. Vertex Pharmaceuticals: Known for its work in gene editing and regenerative medicine.

Risk Factors

Like any biotechnology company, Lineage Cell Therapeutics faces several risks that could impact its business operations and financial performance:

  1. Regulatory Risks: The development and approval of cell therapies are subject to stringent regulatory requirements, which can lead to delays or failures in obtaining approval.
  2. Market Dependence: The company’s success depends on the commercial viability of its therapies, which may face competition or fail to gain market acceptance.
  3. Supply Chain Disruptions: The manufacturing of cell therapies requires specialized materials and equipment, which could be affected by supply chain disruptions.
  4. Financial Risks: As a clinical-stage company, Lineage relies on external funding to support its operations. Any challenges in securing funding could impact its ability to advance its pipeline.
  5. Intellectual Property Risks: The company’s success depends on its ability to protect its intellectual property and avoid infringement claims.

Recent Developments

Lineage Cell Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  1. OpRegen® Clinical Trials: The company reported positive interim results from its Phase 1/2a clinical trial of OpRegen® for dry AMD, demonstrating improved visual acuity and safety.
  2. Partnership with Roche and Genentech: Lineage entered into a strategic collaboration with Roche and Genentech to develop and commercialize OpRegen®.
  3. AST-OPC1 Progress: The company announced advancements in the clinical development of AST-OPC1 for spinal cord injuries, including the initiation of new clinical trials.
  4. VAC2 Updates: Lineage continues to evaluate VAC2 in collaboration with Cancer Research UK, with promising preclinical and early clinical data.
  5. Manufacturing Expansion: The company invested in expanding its manufacturing capabilities to support the production of its cell therapy products.

Investment Considerations

Investors considering Lineage Cell Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Lineage has a robust pipeline of cell therapy products targeting high-value markets with unmet medical needs.
  • Strategic Partnerships: Collaborations with industry leaders like Roche and Genentech enhance the company’s development and commercialization capabilities.
  • Experienced Leadership: The management team has a proven track record in advancing innovative therapies.
  • Grant Funding: Non-dilutive funding from organizations like CIRM reduces financial risk.

Risks

  • Clinical and Regulatory Risks: The success of the company’s therapies depends on positive clinical trial outcomes and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, Lineage relies on external funding, which may not always be available.
  • Market Competition: The biotechnology sector is highly competitive, with numerous companies developing similar therapies.

Conclusion

Lineage Cell Therapeutics is at the forefront of regenerative medicine, leveraging its expertise in cell therapy to address unmet medical needs in ophthalmology, neurology, and oncology. With a strong pipeline, strategic partnerships, and a commitment to innovation, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies before making investment decisions.